Download PDF
Semin Respir Crit Care Med 2024; 45(02): 143-157
DOI: 10.1055/s-0044-1779016
Review Article

Definition, Epidemiology, and Pathogenesis of Severe Community-Acquired Pneumonia

Rodrigo Cavallazzi
1   Division of Pulmonary, Critical Care Medicine, and Sleep Disorders, University of Louisville, Louisville, Kentucky
,
Julio A. Ramirez
2   Norton Infectious Diseases Institute, Norton Healthcare, Louisville, Kentucky
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

The clinical presentation of community-acquired pneumonia (CAP) can vary widely among patients. While many individuals with mild symptoms can be managed as outpatients with excellent outcomes, there is a distinct subgroup of patients who present with severe CAP. In these cases, the mortality rate can reach approximately 25% within 30 days and even up to 50% within a year. It is crucial to focus attention on these patients who are at higher risk. Among the various definitions of severe CAP found in the literature, one commonly used criterion is the requirement for admission to intensive care unit. Notable epidemiological characteristics of these patients include the impact of acute cardiovascular diseases on clinical outcomes and the enduring, independent effect of pneumonia on long-term outcomes. Factors such as pathogen virulence, the presence of comorbidities, and the host response are important contributors to the pathogenesis of severe CAP. In these patients, the host response may be dysregulated and compartmentalized. Gaining a better understanding of the epidemiology and pathogenesis of severe CAP will provide a foundation for the development of new therapies for this condition. This manuscript aims to review the definition, epidemiology, and pathogenesis of severe CAP, shedding light on important aspects that can aid in the improvement of patient care and outcomes.

Keywords

pneumonia - epidemiology - pathogenesis - mortality - definition


Publication History

Article published online:
08 February 2024

© 2024. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 GBD 2019 LRI Collaborators. Age-sex differences in the global burden of lower respiratory infections and risk factors, 1990-2019: results from the Global Burden of Disease Study 2019. Lancet Infect Dis 2022; 22 (11) 1626-1647
    Google Scholar
  • 2 World Health Organization. The top 10 causes of death. Accessed March 30, 2023 at: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death
    Google Scholar
  • 3 GBD 2016 Lower Respiratory Infections Collaborators. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Infect Dis 2018; 18 (11) 1191-1210
    Google Scholar
  • 4 Ramirez JA, Wiemken TL, Peyrani P. et al; University of Louisville Pneumonia Study Group. Adults hospitalized with pneumonia in the United States: incidence, epidemiology, and mortality. Clin Infect Dis 2017; 65 (11) 1806-1812
    Google Scholar
  • 5 Fine MJ, Auble TE, Yealy DM. et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336 (04) 243-250
    Google Scholar
  • 6 Cavallazzi R, Furmanek S, Arnold FW. et al. The burden of community-acquired pneumonia requiring admission to ICU in the United States. Chest 2020; 158 (03) 1008-1016
    Google Scholar
  • 7 Niederman MS, Mandell LA, Anzueto A. et al; American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163 (07) 1730-1754
    Google Scholar
  • 8 Restrepo MI, Mortensen EM, Rello J, Brody J, Anzueto A. Late admission to the ICU in patients with community-acquired pneumonia is associated with higher mortality. Chest 2010; 137 (03) 552-557
    Google Scholar
  • 9 Niederman MS, Bass Jr JB, Campbell GD. et al; American Thoracic Society. Medical Section of the American Lung Association. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis 1993; 148 (05) 1418-1426
    Google Scholar
  • 10 Ewig S, Ruiz M, Mensa J. et al. Severe community-acquired pneumonia. Assessment of severity criteria. Am J Respir Crit Care Med 1998; 158 (04) 1102-1108
    Google Scholar
  • 11 Mandell LA, Wunderink RG, Anzueto A. et al; Infectious Diseases Society of America, American Thoracic Society. Infectious Diseases Society of America/American . NEWS2 Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 (Suppl. 02) S27-S72
    Google Scholar
  • 12 Metlay JP, Waterer GW, Long AC. et al. Diagnosis and treatment of adults with community-acquired pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med 2019; 200 (07) e45-e67
    Google Scholar
  • 13 Gearhart AM, Furmanek S, English C, Ramirez J, Cavallazzi R. Predicting the need for ICU admission in community-acquired pneumonia. Respir Med 2019; 155: 61-65
    Google Scholar
  • 14 Charles PG, Wolfe R, Whitby M. et al; Australian Community-Acquired Pneumonia Study Collaboration. SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Dis 2008; 47 (03) 375-384
    Google Scholar
  • 15 Neill AM, Martin IR, Weir R. et al. Community acquired pneumonia: aetiology and usefulness of severity criteria on admission. Thorax 1996; 51 (10) 1010-1016
    Google Scholar
  • 16 Lim WS, van der Eerden MM, Laing R. et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003; 58 (05) 377-382
    Google Scholar
  • 17 Prytherch DR, Smith GB, Schmidt PE, Featherstone PI. ViEWS–towards a national early warning score for detecting adult inpatient deterioration. Resuscitation 2010; 81 (08) 932-937
    Google Scholar
  • 18 Corfield AR, Lees F, Zealley I. et al; Scottish Trauma Audit Group Sepsis Steering Group. Utility of a single early warning score in patients with sepsis in the emergency department. Emerg Med J 2014; 31 (06) 482-487
    Google Scholar
  • 19 Royal College of Physicians. National Early Warning Score (NEWS) 2: standardising the assessment of acute-illness severity in the NHS. Updated report of a working Party. RCP London; 2017
    Google Scholar
  • 20 Martin-Loeches I, Torres A, Nagavci B. et al. ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia. Intensive Care Med 2023; 49 (06) 615-632
    Google Scholar
  • 21 Murthy S, Leligdowicz A, Adhikari NK. Intensive care unit capacity in low-income countries: a systematic review. PLoS One 2015; 10 (01) e0116949
    Google Scholar
  • 22 Storms AD, Chen J, Jackson LA. et al. Rates and risk factors associated with hospitalization for pneumonia with ICU admission among adults. BMC Pulm Med 2017; 17 (01) 208
    Google Scholar
  • 23 Cavallazzi R, Wiemken T, Arnold FW. et al. Outcomes in patients with community-acquired pneumonia admitted to the intensive care unit. Respir Med 2015; 109 (06) 743-750
    Google Scholar
  • 24 Lisboa T, Blot S, Waterer GW. et al. Radiologic progression of pulmonary infiltrates predicts a worse prognosis in severe community-acquired pneumonia than bacteremia. Chest 2009; 135 (01) 165-172
    Google Scholar
  • 25 Paganin F, Lilienthal F, Bourdin A. et al. Severe community-acquired pneumonia: assessment of microbial aetiology as mortality factor. Eur Respir J 2004; 24 (05) 779-785
    Google Scholar
  • 26 Jain S, Self WH, Wunderink RG. et al; CDC EPIC Study Team. Community-acquired pneumonia requiring hospitalization among U.S. adults. N Engl J Med 2015; 373 (05) 415-427
    Google Scholar
  • 27 Cillóniz C, Ewig S, Polverino E. et al. Microbial aetiology of community-acquired pneumonia and its relation to severity. Thorax 2011; 66 (04) 340-346
    Google Scholar
  • 28 Quah J, Jiang B, Tan PC, Siau C, Tan TY. Impact of microbial aetiology on mortality in severe community-acquired pneumonia. BMC Infect Dis 2018; 18 (01) 451
    Google Scholar
  • 29 Ramirez JA, Musher DM, Evans SE. et al. Treatment of community-acquired pneumonia in immunocompromised adults: a consensus statement regarding initial strategies. Chest 2020; 158 (05) 1896-1911
    Google Scholar
  • 30 Cillóniz C, Torres A, Niederman M. et al. Community-acquired pneumonia related to intracellular pathogens. Intensive Care Med 2016; 42 (09) 1374-1386
    Google Scholar
  • 31 Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax 2012; 67 (01) 71-79
    Google Scholar
  • 32 Cowgill KD, Lucas CE, Benson RF. et al. Recurrence of legionnaires disease at a hotel in the United States Virgin Islands over a 20-year period. Clin Infect Dis 2005; 40 (08) 1205-1207
    Google Scholar
  • 33 Silk BJ, Moore MR, Bergtholdt M. et al. Eight years of Legionnaires' disease transmission in travellers to a condominium complex in Las Vegas, Nevada. Epidemiol Infect 2012; 140 (11) 1993-2002
    Google Scholar
  • 34 Burk M, El-Kersh K, Saad M, Wiemken T, Ramirez J, Cavallazzi R. Viral infection in community-acquired pneumonia: a systematic review and meta-analysis. Eur Respir Rev 2016; 25 (140) 178-188
    Google Scholar
  • 35 Karhu J, Ala-Kokko TI, Vuorinen T, Ohtonen P, Syrjälä H. Lower respiratory tract virus findings in mechanically ventilated patients with severe community-acquired pneumonia. Clin Infect Dis 2014; 59 (01) 62-70
    Google Scholar
  • 36 Choi SH, Hong SB, Ko GB. et al. Viral infection in patients with severe pneumonia requiring intensive care unit admission. Am J Respir Crit Care Med 2012; 186 (04) 325-332
    Google Scholar
  • 37 Ruiz M, Ewig S, Marcos MA. et al. Etiology of community-acquired pneumonia: impact of age, comorbidity, and severity. Am J Respir Crit Care Med 1999; 160 (02) 397-405
    Google Scholar
  • 38 McBride JA, Gauthier GM, Klein BS. Clinical manifestations and treatment of blastomycosis. Clin Chest Med 2017; 38 (03) 435-449
    Google Scholar
  • 39 Lemos LB, Baliga M, Guo M. Acute respiratory distress syndrome and blastomycosis: presentation of nine cases and review of the literature. Ann Diagn Pathol 2001; 5 (01) 1-9
    Google Scholar
  • 40 Ashraf N, Kubat RC, Poplin V. et al. Re-drawing the maps for endemic mycoses. Mycopathologia 2020; 185 (05) 843-865
    Google Scholar
  • 41 Cavallazzi R, Wiemken T, Christensen D. et al; Community-Acquired Pneumonia Organization (CAPO) Investigators. Predicting Mycobacterium tuberculosis in patients with community-acquired pneumonia. Eur Respir J 2014; 43 (01) 178-184
    Google Scholar
  • 42 Cavallazzi R, Maurici R, Ramirez JA. Tuberculosis is always a possibility (even in the intensive care unit). Rev Bras Ter Intensiva 2016; 28 (02) 97-99
    Google Scholar
  • 43 Naderi H, Sheybani F, Erfani SS, Amiri B, Nooghabi MJ. The mask of acute bacterial pneumonia may disguise the face of tuberculosis. Electron Physician 2017; 9 (03) 3943-3949
    Google Scholar
  • 44 Friedman ND, Kaye KS, Stout JE. et al. Health care–associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med 2002; 137 (10) 791-797
    Google Scholar
  • 45 American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171 (04) 388-416
    Google Scholar
  • 46 Shindo Y, Ito R, Kobayashi D. et al. Risk factors for drug-resistant pathogens in community-acquired and healthcare-associated pneumonia. Am J Respir Crit Care Med 2013; 188 (08) 985-995
    Google Scholar
  • 47 Aliberti S, Di Pasquale M, Zanaboni AM. et al. Stratifying risk factors for multidrug-resistant pathogens in hospitalized patients coming from the community with pneumonia. Clin Infect Dis 2012; 54 (04) 470-478
    Google Scholar
  • 48 Venditti M, Falcone M, Corrao S, Licata G, Serra P. Study Group of the Italian Society of Internal Medicine. Outcomes of patients hospitalized with community-acquired, health care-associated, and hospital-acquired pneumonia. Ann Intern Med 2009; 150 (01) 19-26
    Google Scholar
  • 49 Rhee C, Kadri SS, Dekker JP. et al; CDC Prevention Epicenters Program. Prevalence of antibiotic-resistant pathogens in culture-proven sepsis and outcomes associated with inadequate and broad-spectrum empiric antibiotic use. JAMA Netw Open 2020; 3 (04) e202899
    Google Scholar
  • 50 Kalil AC, Metersky ML, Klompas M. et al. Executive summary: management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 2016; 63 (05) 575-582
    Google Scholar
  • 51 Madaras-Kelly KJ, Remington RE, Sloan KL, Fan VS. Guideline-based antibiotics and mortality in healthcare-associated pneumonia. J Gen Intern Med 2012; 27 (07) 845-852
    Google Scholar
  • 52 Shorr AF, Zilberberg MD, Reichley R. et al. Validation of a clinical score for assessing the risk of resistant pathogens in patients with pneumonia presenting to the emergency department. Clin Infect Dis 2012; 54 (02) 193-198
    Google Scholar
  • 53 Cheng GS, Crothers K, Aliberti S. et al. Immunocompromised host pneumonia: definitions and diagnostic criteria: an official American Thoracic Society workshop report. Ann Am Thorac Soc 2023; 20 (03) 341-353
    Google Scholar
  • 54 Di Pasquale MF, Sotgiu G, Gramegna A. et al; GLIMP Investigators. Prevalence and etiology of community-acquired pneumonia in immunocompromised patients. Clin Infect Dis 2019; 68 (09) 1482-1493
    Google Scholar
  • 55 Ramirez J, Aliberti S, Mirsaeidi M. et al. Acute myocardial infarction in hospitalized patients with community-acquired pneumonia. Clin Infect Dis 2008; 47 (02) 182-187
    Google Scholar
  • 56 Corrales-Medina VF, Musher DM, Wells GA, Chirinos JA, Chen L, Fine MJ. Cardiac complications in patients with community-acquired pneumonia: incidence, timing, risk factors, and association with short-term mortality. Circulation 2012; 125 (06) 773-781
    Google Scholar
  • 57 Aliberti S, Amir A, Peyrani P. et al. Incidence, etiology, timing, and risk factors for clinical failure in hospitalized patients with community-acquired pneumonia. Chest 2008; 134 (05) 955-962
    Google Scholar
  • 58 Mortensen EM, Coley CM, Singer DE. et al. Causes of death for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team cohort study. Arch Intern Med 2002; 162 (09) 1059-1064
    Google Scholar
  • 59 Hedlund JU, Ortqvist AB, Kalin ME, Granath F. Factors of importance for the long term prognosis after hospital treated pneumonia. Thorax 1993; 48 (08) 785-789
    Google Scholar
  • 60 Bordon J, Wiemken T, Peyrani P. et al; CAPO Study Group. Decrease in long-term survival for hospitalized patients with community-acquired pneumonia. Chest 2010; 138 (02) 279-283
    Google Scholar
  • 61 Quinton LJ, Walkey AJ, Mizgerd JP. Integrative physiology of pneumonia. Physiol Rev 2018; 98 (03) 1417-1464
    Google Scholar
  • 62 Silva MT. When two is better than one: macrophages and neutrophils work in concert in innate immunity as complementary and cooperative partners of a myeloid phagocyte system. J Leukoc Biol 2010; 87 (01) 93-106
    Google Scholar
  • 63 Tazi A, Nioche S, Chastre J, Smiéjan JM, Hance AJ. Spontaneous release of granulocyte colony-stimulating factor (G-CSF) by alveolar macrophages in the course of bacterial pneumonia and sarcoidosis: endotoxin-dependent and endotoxin-independent G-CSF release by cells recovered by bronchoalveolar lavage. Am J Respir Cell Mol Biol 1991; 4 (02) 140-147
    Google Scholar
  • 64 Knapp S, Hareng L, Rijneveld AW. et al. Activation of neutrophils and inhibition of the proinflammatory cytokine response by endogenous granulocyte colony-stimulating factor in murine pneumococcal pneumonia. J Infect Dis 2004; 189 (08) 1506-1515
    Google Scholar
  • 65 Maus U, Rosseau S, Knies U, Seeger W, Lohmeyer J. Expression of pro-inflammatory cytokines by flow-sorted alveolar macrophages in severe pneumonia. Eur Respir J 1998; 11 (03) 534-541
    Google Scholar
  • 66 Soong G, Reddy B, Sokol S, Adamo R, Prince A. TLR2 is mobilized into an apical lipid raft receptor complex to signal infection in airway epithelial cells. J Clin Invest 2004; 113 (10) 1482-1489
    Google Scholar
  • 67 Jones MR, Simms BT, Lupa MM, Kogan MS, Mizgerd JP. Lung NF-kappaB activation and neutrophil recruitment require IL-1 and TNF receptor signaling during pneumococcal pneumonia. J Immunol 2005; 175 (11) 7530-7535
    Google Scholar
  • 68 Dallaire F, Ouellet N, Bergeron Y. et al. Microbiological and inflammatory factors associated with the development of pneumococcal pneumonia. J Infect Dis 2001; 184 (03) 292-300
    Google Scholar
  • 69 Nauseef WM. How human neutrophils kill and degrade microbes: an integrated view. Immunol Rev 2007; 219: 88-102
    Google Scholar
  • 70 Brieland J, Freeman P, Kunkel R. et al. Replicative Legionella pneumophila lung infection in intratracheally inoculated A/J mice. A murine model of human Legionnaires' disease. Am J Pathol 1994; 145 (06) 1537-1546
    Google Scholar
  • 71 Calbo E, Alsina M, Rodríguez-Carballeira M, Lite J, Garau J. Systemic expression of cytokine production in patients with severe pneumococcal pneumonia: effects of treatment with a beta-lactam versus a fluoroquinolone. Antimicrob Agents Chemother 2008; 52 (07) 2395-2402
    Google Scholar
  • 72 Calbo E, Alsina M, Rodríguez-Carballeira M, Lite J, Garau J. The impact of time on the systemic inflammatory response in pneumococcal pneumonia. Eur Respir J 2010; 35 (03) 614-618
    Google Scholar
  • 73 Crisafulli E, Menéndez R, Huerta A. et al. Systemic inflammatory pattern of patients with community-acquired pneumonia with and without COPD. Chest 2013; 143 (04) 1009-1017
    Google Scholar
  • 74 Sørensen TI, Nielsen GG, Andersen PK, Teasdale TW. Genetic and environmental influences on premature death in adult adoptees. N Engl J Med 1988; 318 (12) 727-732
    Google Scholar
  • 75 Menéndez R, Sahuquillo-Arce JM, Reyes S. et al. Cytokine activation patterns and biomarkers are influenced by microorganisms in community-acquired pneumonia. Chest 2012; 141 (06) 1537-1545
    Google Scholar
  • 76 Song H, Tang L, Xu M. et al. CD86 polymorphism affects pneumonia-induced sepsis by decreasing gene expression in monocytes. Inflammation 2015; 38 (02) 879-885
    Google Scholar
  • 77 Dessing MC, van der Sluijs KF, Spek CA, van der Poll T. Gene expression profiles in murine influenza pneumonia. J Innate Immun 2009; 1 (04) 366-375
    Google Scholar
  • 78 Martin-Loeches I, Papiol E, Almansa R, López-Campos G, Bermejo-Martin JF, Rello J. Intubated patients developing tracheobronchitis or pneumonia have distinctive complement system gene expression signatures in the pre-infection period: a pilot study. Med Intensiva (Madrid) 2012; 36 (04) 257-263
    Google Scholar
  • 79 Swanson JM, Wood GC, Xu L. et al. Developing a gene expression model for predicting ventilator-associated pneumonia in trauma patients: a pilot study. PLoS One 2012; 7 (08) e42065
    Google Scholar
  • 80 Bordon J, Aliberti S, Fernandez-Botran R. et al. Understanding the roles of cytokines and neutrophil activity and neutrophil apoptosis in the protective versus deleterious inflammatory response in pneumonia. Int J Infect Dis 2013; 17 (02) e76-e83
    Google Scholar
  • 81 Antunes G, Evans SA, Lordan JL, Frew AJ. Systemic cytokine levels in community-acquired pneumonia and their association with disease severity. Eur Respir J 2002; 20 (04) 990-995
    Google Scholar
  • 82 Igonin AA, Armstrong VW, Shipkova M, Lazareva NB, Kukes VG, Oellerich M. Circulating cytokines as markers of systemic inflammatory response in severe community-acquired pneumonia. Clin Biochem 2004; 37 (03) 204-209
    Google Scholar
  • 83 Menéndez R, Cavalcanti M, Reyes S. et al. Markers of treatment failure in hospitalised community acquired pneumonia. Thorax 2008; 63 (05) 447-452
    Google Scholar
  • 84 Ramírez P, Ferrer M, Martí V. et al. Inflammatory biomarkers and prediction for intensive care unit admission in severe community-acquired pneumonia. Crit Care Med 2011; 39 (10) 2211-2217
    Google Scholar
  • 85 MacFadden DK, Edelson JD, Hyland RH, Rodriguez CH, Inouye T, Rebuck AS. Corticosteroids as adjunctive therapy in treatment of Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome. Lancet 1987; 1 (8548) 1477-1479
    Google Scholar
  • 86 Montaner JS, Lawson LM, Levitt N, Belzberg A, Schechter MT, Ruedy J. Corticosteroids prevent early deterioration in patients with moderately severe Pneumocystis carinii pneumonia and the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1990; 113 (01) 14-20
    Google Scholar
  • 87 Horby P, Lim WS, Emberson JR. et al; RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med 2021; 384 (08) 693-704
    Google Scholar
  • 88 RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 2021; 397 (10285): 1637-1645
    Google Scholar
  • 89 Kalil AC, Patterson TF, Mehta AK. et al; ACTT-2 Study Group Members. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med 2021; 384 (09) 795-807
    Google Scholar
  • 90 Lansbury L, Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam J, Lim WS. Corticosteroids as adjunctive therapy in the treatment of influenza. Cochrane Database Syst Rev 2019; 2 (02) CD010406
    Google Scholar
  • 91 Torres A, Sibila O, Ferrer M. et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA 2015; 313 (07) 677-686
    Google Scholar
  • 92 Zhang J, Hao Y, Ou W. et al. Serum interleukin-6 is an indicator for severity in 901 patients with SARS-CoV-2 infection: a cohort study. J Transl Med 2020; 18 (01) 406
    Google Scholar
  • 93 Galván-Román JM, Rodríguez-García SC, Roy-Vallejo E. et al; REINMUN-COVID Group. IL-6 serum levels predict severity and response to tocilizumab in COVID-19: an observational study. J Allergy Clin Immunol 2021; 147 (01) 72-80.e8
    Google Scholar
  • 94 Dequin PF, Meziani F, Quenot JP. et al; CRICS-TriGGERSep Network. Hydrocortisone in severe community-acquired pneumonia. N Engl J Med 2023; 388 (21) 1931-1941
    Google Scholar
  • 95 Meduri GU, Shih MC, Bridges L. et al; ESCAPe Study Group. Low-dose methylprednisolone treatment in critically ill patients with severe community-acquired pneumonia. Intensive Care Med 2022; 48 (08) 1009-1023
    Google Scholar